INTERCEPT PHARMACEUTICALS IN's ticker is and the CUSIP is 45845PAB4. A total of 15 filers reported holding INTERCEPT PHARMACEUTICALS IN in Q3 2023. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2021 | $5,760,000 | +545.7% | 8,925,000 | +495.0% | 0.05% | +600.0% |
| Q4 2020 | $892,000 | -14.1% | 1,500,000 | 0.0% | 0.01% | -22.2% |
| Q3 2020 | $1,038,000 | -4.6% | 1,500,000 | 0.0% | 0.01% | -18.2% |
| Q2 2020 | $1,088,000 | -17.5% | 1,500,000 | 0.0% | 0.01% | -42.1% |
| Q1 2020 | $1,318,000 | -92.9% | 1,500,000 | -89.3% | 0.02% | -91.2% |
| Q4 2019 | $18,577,000 | +7.7% | 14,000,000 | -26.3% | 0.22% | -1.4% |
| Q3 2019 | $17,254,000 | -8.7% | 19,000,000 | 0.0% | 0.22% | -11.3% |
| Q2 2019 | $18,904,000 | – | 19,000,000 | – | 0.25% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| HIGHBRIDGE CAPITAL MANAGEMENT LLC | 55,943,000 | $39,071,000 | 2.11% |
| PenderFund Capital Management Ltd. | 5,000,000 | $4,719,000 | 1.31% |
| Opti Capital Management, LP | 13,246,000 | $9,340,000 | 1.14% |
| Context Partners Fund, L.P. | 7,485,000 | $5,145,000 | 1.12% |
| Context Capital Management, LLC | 7,485,000 | $5,145,000 | 1.12% |
| Soros Fund Management | 19,552,000 | $13,548,000 | 0.33% |
| ADVENT CAPITAL MANAGEMENT /DE/ | 18,604,000 | $12,963,000 | 0.29% |
| Senvest Management, LLC | 5,000,000 | $3,465,000 | 0.20% |
| CSS LLC/IL | 2,825,000 | $1,957,000 | 0.09% |
| GABELLI & Co INVESTMENT ADVISERS, INC. | 350,000 | $243,000 | 0.04% |